Amplification and co-regulators of androgen receptor gene in prostate cancer

Experimental Oncology

Volumn 31, Issue 1, 2009, Pages 3-8

  Golias, Ch ^a   Iliadis, I ^a   Peschos, D ^a   Charalabopoulos, K ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Androgen receptors; Co regulators; Prostate Cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEIN ARA 267 A; PROTEIN ARA 54; PROTEIN ARA 55; PROTEIN ARA 70; PROTEIN ART 27; PROTEIN FHL 2; REGULATOR PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER RISK; CARCINOGENESIS; GENE AMPLIFICATION; GENE INTERACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PREVALENCE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PROSTATE TUMOR;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 65549129120     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-319 (Pubitemid 27036612)
2. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 255-264 (Pubitemid 40128246)
3. Palmberg C, Koivisto P, Kakkola L, et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1996-1997
4. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004; 93: 233-241 (Pubitemid 44264201)
5. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006; 99: 362-372 (Pubitemid 44435554)
6. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-344 (Pubitemid 44435552)
7. Bebermeier JH, Brooks JD, DePrimo SE, et al. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J Mol Med 2006; 84: 919-931 (Pubitemid 44655870)
8. Kim J, Jia L, Stallcup MR, Coetzee GA. The role of protein kinase A pathway and cAMP responsive elementbinding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J Mol Endocrinol 2005; 34: 107-118 (Pubitemid 40305553)
9. Miyamoto H, Rahman M, Takatera H, et al. A dominant- negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 2002; 277: 4609-4617 (Pubitemid 34968489)
10. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23: 175-200.
11. Linja MJ, Porkka KP, Kang Z, et al. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004; 10: 1032-1040 (Pubitemid 38202234)
12. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004; 279: 7119-7130 (Pubitemid 38248859)
13. Yang Z, Chang YJ, Miyamoto H, et al. Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54. Endocrinology 2007; 148: 1340-1349 (Pubitemid 46272797)
14. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. : Proc Natl Acad Sci USA 2003; 100: 5124-5129 (Pubitemid 36542669)
15. Fujimoto N, Miyamoto H, Mizokami A, et al. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest 2007; 25: 32-37 (Pubitemid 46423588)
16. Miyoshi Y, Ishiguro H, Uemura H, et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003; 56: 280-286 (Pubitemid 36988748)
17. Wang X, Yang Y, Guo X, et al. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 2002; 277: 15426-15431 (Pubitemid 34967806)
18. Yeh S, Sampson ER, Lee DK, et al. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer. J Formos Med Assoc 2000; 99: 885-894 (Pubitemid 32016394)
19. Hu YC, Yeh S, Yeh SD, et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004; 279: 33438-33446
20. Niu Y, Yeh S, Miyamoto H, et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008; 68: 7110-7119
21. Hu YC, Yeh S, Yeh SD, et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004; 279: 33438-33446 (Pubitemid 39062993)
22. Gregory CW, Johnson RT Jr, Presnell SC, et al. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase functions in the CWR22 human prostate cancer xenograft. J Androl 2001; 22: 537-548
23. Nessler-Menardi C, Jotova I, Culig Z, et al. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 2000; 45: 124-131 (Pubitemid 30747159)
24. Mai T, Wang X, Zhang Z, et al. Androgen receptor coregulator ARA267-alpha interacts with death receptor-6 revealed by the yeast two-hybrid. Sci China C Life Sci 2004; 47: 442-448 (Pubitemid 43758767)
25. Wang X, Mai TJ, Niu YN, et al. Identification of proteins interacting with androgen receptor - associated coregulator 267-alpha (ARA267-alpha) with the yeast two-hybrid system. Beijing Da Xue Xue Bao 2004; 36: 514-518
26. Wang X, Yeh S, Wu G, et al. Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J Biol Chem 2001; 276: 40417-40423 (Pubitemid 37373179)
27. Li W, Cavasotto CN, Cardozo T, et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 2005; 19: 2273-2282 (Pubitemid 41252822)
28. Taneja SS, Ha S, Swenson NK, et al. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 2004; 279: 13944-13952 (Pubitemid 38468927)
29. Markus SM, Taneja SS, Logan SK, et al. Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol Biol Cell 2002; 13: 670-682 (Pubitemid 34165092)
30. Charalabopoulos K, Binolis J, Karkabounas S. Adhesion molecules in carcinogenesis. Exp Oncol 2002; 24: 249-257
31. Bonitsis N, Batistatou A, Karantima S, Charalabopoulos K. The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 2006; 28: 187-193 (Pubitemid 44735907)
32. Lu W, Tinsley HN, Keeton A, et al. Suppression of Wnt/ beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 2009; 602: 8-14.
33. Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res 2007; 67: 10592-10599
34. Nair SS, Guo Z, Mueller JM, et al. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 2007; 21: 613-624 (Pubitemid 46310184)
35. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66: 11341-11347 (Pubitemid 46009965)
36. Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 2005; 12: 390-397 (Pubitemid 40965890)
37. Fantinato AP, Tobias-Machado M, Fonseca F, et al. Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients. Tumori 2007; 93: 467-472 (Pubitemid 350203920)
38. Osman I, Mikhail M, Shuch B, et al. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005; 174: 2174-2177 (Pubitemid 41611768)
39. Graham TR, Odero-Marah VA, Chung LW, et al. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate 2008; 69: 168-180
40. Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, et al. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia 2007; 9: 614-624
41. Kawada M, Inoue H, Usami I, et al. Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance. Cancer Lett 2006; 242: 46-52. (Pubitemid 44485290)
42. Mori R, Wang Q, Quek ML, et al. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Anticancer Res 2008; 28: 425-430 (Pubitemid 351362848)
43. Mori R, Xiong S, Wang Q, et al. Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 2008; 69: 12-23.
44. Wang J, Zhou JG, Huang CF. Research on the structure of the PSA promoter and the mechanisms of its expression regulation. Yi Chuan 2004; 26: 739-744
45. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin- 6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008; 122: 1521-1529 (Pubitemid 351294960)
46. Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin- 6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95: 497-505. (Pubitemid 41420180)